vasopressin analogue
Desmopressin dose
Answer
FDA label for Desmopressin Acetate: The recommended dosage is 0.3 mcg/kg actual body weight (to a maximum of 20 mcg) administered by intravenous infusion over 15 minutes to 30 minutes. Half-life on the label: 2.8 hours. Trials with posted results tested 10 doses, most often 50 μg, 100 μg, 25 μg.
Not dosing advice.
FDA LABEL
What the approved labels state
Desmopressin Acetate ANDA210223 · label of 2026-08-27 Regulator
The recommended dosage is 0.3 mcg/kg actual body weight (to a maximum of 20 mcg) administered by intravenous infusion over 15 minutes to 30 minutes.
Stimate NDA020355 · label of 2026-07-22 Regulator
The recommended dosage for patients weighing at least 50 kg is 300 mcg intranasal spray (one spray in each nostril).
Half-life: 2.8 hours (section 12.3).
DESMODA NDA219873 · label of 2026-03-02 Regulator
Recommended starting dosage of DESMODA for adults and pediatric patients is 0.05 mg orally twice daily.
Half-life: 3.6 hours (section 12.3).
DDAVP NDA018938 · label of 2022-09-28 Regulator
The recommended starting dose of DDAVP Injection is 1/10 th the daily maintenance intranasal dose administered by subcutaneous or intravenous injection as one or two divided doses Hemophilia A and von Willebrand's Disease (Type I): The recommended dosage is 0.3 mcg/kg actual body weight (to a maximum of 20 mcg) administered by intravenous infusion over 15 minutes to 30 minutes.
Half-life: 2.8 hours (section 12.3).
IN TRIALS
Doses tested in 18 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 50 μg | 3 | 727 | 3 |
| 100 μg | 3 | 714 | 3 |
| 25 μg | 3 | 655 | 3 |
| 10 μg | 2 | 493 | 3 |
| 75 μg | 1 | 224 | 3 |
| 0.1 mg | 1 | 137 | - |
| 25 mcg | 2 | 70 | 2 |
| 10 mcg | 1 | 48 | 2 |
| 100 mcg | 1 | 47 | 2 |
| 50 mcg | 1 | 44 | 2 |
Trial register Read from the titles of arms that received Desmopressin (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.